E2F7 serves as a potential prognostic biomarker for lung adenocarcinoma

Lin，Shengcheng1; Yu，Xiangyang1; Yan，Haojie2,3; Xu，Yafei4; Ma，Kai1; Wang，Xiaoliang5; Liu，Yeqing1; Xie，Ahuan5; Yu，Zhentao1

2024-01-19

10.1097/MD.0000000000034342

Medicine (United States)   影响因子和分区

0025-7974

1536-5964

E2F transcription factors (E2Fs) are a family of transcription factors critical regulators of the cell cycle, apoptosis, and differentiation, thus influencing tumorigenesis. However, the specific roles of E2Fs in lung adenocarcinoma (LUAD) remain unclear. Data from The Cancer Genome Atlas (TCGA) were used. R version. 4.0.3 and multiple databases (TIMER, cBioportal, gene expression profile interaction analysis [GEPIA], LinkedOmics, and CancerSEA) were utilized to investigate mRNA expression, mutational analysis, prognosis, clinical correlations, co-expressed gene, pathway and network, and single-cell analyses. Immunohistochemistry (IHC) confirmed that E2F transcription factor 7 (E2F7) correlated with LUAD. Among the E2Fs, E2F7 was identified by constructing a prognostic model most significantly associated with overall survival (OS) in LUAD patients. The univariate and multivariate Cox regression analyses showed that E2F7, p-T stage, and p-TNM stage were closely related to OS and progression-free survival (PFS) (P < .05) in LUAD. E2F 7/8 were also identified as significantly associated with tumor stage in the GEPIA database. Compared with paracancerous tissues, E2F7 was up-regulated in LUAD by IHC, and E2F7 might be positively correlated with larger tumors and higher TNM stages. E2F7 may primarily regulate DNA repair, damage, and cell cycle processes and thus affect LUAD tumorigenesis, invasion, and metastasis by LinkedOmics and CancerSEA. E2F7 serves as a potential prognostic biomarker for LUAD.

bioinformatic analysis E2F transcription factor (E2F7) lung adenocarcinoma prognostic biomarker

SCI

英语

其他

CLINICAL MEDICINE

2-s2.0-85182828862

Scopus

1.Department of Thoracic Surgery,National Cancer Center,National Clinical Research Center for Cancer,Cancer Hospital and Shenzhen Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Shenzhen,China
2.Translational Medicine Collaborative Innovation Center,Shenzhen People's Hospital,The Second Clinical Medical College,Jinan University,The First Affifiliated Hospital,Southern University of Science and Technology,Shenzhen,China
3.Basic Medicine Postdoctoral Research Station,Jinan University,Guangzhou,China
4.Department of Anesthesiology,Shunde Hospital of Southern Medical University,The First People's Hospital of Shunde Foshan,Foshan,China
5.Department of Pathology,National Cancer Center,National Clinical Research Center for Cancer,Cancer Hospital and Shenzhen Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Shenzhen,China

Lin，Shengcheng,Yu，Xiangyang,Yan，Haojie,et al. E2F7 serves as a potential prognostic biomarker for lung adenocarcinoma[J]. Medicine (United States),2024,103(3).

Lin，Shengcheng.,Yu，Xiangyang.,Yan，Haojie.,Xu，Yafei.,Ma，Kai.,...&Yu，Zhentao.(2024).E2F7 serves as a potential prognostic biomarker for lung adenocarcinoma.Medicine (United States),103(3).

Lin，Shengcheng,et al."E2F7 serves as a potential prognostic biomarker for lung adenocarcinoma".Medicine (United States) 103.3(2024).